Home > Insider Trading > Filing (0001209191-23-054635)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1534133	Calcimedica Inc.	CALC	Pharmaceutical Preparations (2834)	452120079

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1576244	W Eric Roberts	C/O Calcimedica, Inc. 505 Coast S. Blvd. #202 La Jolla CA 92037	Chief Business Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-11-03	3,700	$2.77	20,287	No	4	P	Direct
Common Stock	Acquisiton	2023-11-03	11,249	$2.83	33,494	No	4	P	Indirect	By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,223	Indirect	By FMTC Custodian - Roth IRA FBO Eric W. Roberts
Common Stock	10,661	Indirect	By IRA Financial Trust Company CFBO Eric W. Roberts
Common Stock	356,989	Indirect	By Valence Investments SPV IV, LLC
Common Stock	66,228	Indirect	By Valence Investments SPV V, LLC
Common Stock	316,109	Indirect	By Valence Investments SPV VI, LLC

Footnotes

The weighted average purchase price for the transaction reported was $2.77, and the range of prices were between $2.70 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
The weighted average purchase price for the transaction reported was $2.831, and the range of prices were between $2.67 and $2.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.